Daré Bioscience, Inc.

Daré Bioscience, Inc. company information, Employees & Contact Information

Daré Bioscience® (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. With eight potentially first-in-class women’s health products in development, we are committed to bring to market differentiated products designed to expand treatment options, improve outcomes, and facilitate a better quality of life for women. Vaginal drug delivery is often the optimum delivery approach to achieve these objectives, and IVR technology has become one of our preferred investigational platforms. Our portfolio features innovative IVR technologies including our non-hormonal contraceptive Ovaprene®, which we believe has the potential to disrupt the contraceptive landscape by providing protection for one month, without the use hormones, and our suite of ethylene-vinyl acetate (EVA) matrixed IVRs that can provide flexibility in terms of drug loading, drug delivery, and modulation of release rates across a wide array of molecules, hormones, peptides and proteins, facilitating new indications and applications of the technology. Daré’s EVA IVR technology includes DARE-HRT1 for dual hormone replacement as a potential treatment for the vasomotor symptoms of menopause and DARE-FRT1 for vaginal progesterone delivery in support of fertility and the prevention of pre-term birth. In addition to its novel IVR technologies, Daré is developing a topical formulation of sildenafil, the active ingredient in the blockbuster product Viagra®, for the treatment of female sexual arousal disorder (FSAD) as well as a novel vaginal formulation of the selective estrogen receptor modulator (SERM) tamoxifen to address and alleviate the symptoms of vulvar vaginal atrophy (VVA) for women diagnosed with and treated for hormone-receptor-positive (HR+) breast cancer.

Company Details

Employees
25
Founded
-
Address
3655 Nobel Dr, San Diego,california 92122,united States
Phone
(858) 926-7655
Email
in****@****nce.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Diego, California
Looking for a particular Daré Bioscience, Inc. employee's phone or email?

Daré Bioscience, Inc. Questions

News

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025 - Yahoo Finance

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025 Yahoo Finance

Daré Bioscience Readies First Commercial Product Launch as Multiple Women's Health Solutions Near Market - Stock Titan

Daré Bioscience Readies First Commercial Product Launch as Multiple Women's Health Solutions Near Market Stock Titan

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders - GlobeNewswire

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders GlobeNewswire

$41.8M Received to Date — Daré Bioscience Advances DARE-IDDS Contraception Program, Seeks Partners - Stock Titan

$41.8M Received to Date — Daré Bioscience Advances DARE-IDDS Contraception Program, Seeks Partners Stock Titan

Daré Bioscience Announces Reverse Stock Split - Yahoo Finance

Daré Bioscience Announces Reverse Stock Split Yahoo Finance

Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene - Business Wire

Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene Business Wire

Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic - GlobeNewswire

Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic GlobeNewswire

Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting - Yahoo Finance

Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting Yahoo Finance

Daré Bioscience Announces Common Stock Purchase Agreement - GlobeNewswire

Daré Bioscience Announces Common Stock Purchase Agreement GlobeNewswire

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive - GlobeNewswire

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive GlobeNewswire

Daré Bioscience and Theramex Announce Co-Development and - GlobeNewswire

Daré Bioscience and Theramex Announce Co-Development and GlobeNewswire

Daré Bioscience Announces $2.5 Million Grant Funding - GlobeNewswire

Daré Bioscience Announces $2.5 Million Grant Funding GlobeNewswire

Daré Bioscience Enters into Agreement to Acquire Microchips - GlobeNewswire

Daré Bioscience Enters into Agreement to Acquire Microchips GlobeNewswire

Daré Bioscience Announces Publication of Pharmacokinetics - GlobeNewswire

Daré Bioscience Announces Publication of Pharmacokinetics GlobeNewswire

Top Daré Bioscience, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant